Inhibition of arterial thrombosis by a soluble tissue factor mutant and active site-blocked factors IXa and Xa in the guinea pig

Thrombosis and Haemostasis

Volumn 85, Issue 3, 2001, Pages 475-481

  Himber, J ^a   Refino, C J ^a   Burcklen, L ^a   Roux, S ^a   Kirchhofer, D ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Anticoagulants; Factor IX; Factor VII; Factor X; Thrombosis; Tissue factor

Indexed keywords

ALANINE; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9A; BLOOD CLOTTING FACTOR 9A INHIBITOR; BLOOD CLOTTING INHIBITOR; HEPARIN; LYSINE; RECOMBINANT THROMBOPLASTIN; THROMBOPLASTIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BLEEDING TIME; BLOOD CELL COUNT; BOLUS INJECTION; CONTROLLED STUDY; CUTICLE; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME SUBSTRATE COMPLEX; GUINEA PIG; HEMODYNAMICS; HEMOSTASIS; MALE; METABOLIC INHIBITION; MUTANT; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BINDING; PROTHROMBIN TIME; RECURRENT DISEASE; RISK; THROMBOSIS PREVENTION;

EID: 0035077129     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615608     Document Type: Article

References (52)

1. The tissue factor pathway of blood coagulation
2. The structural basis of function of the TF·VIIa complex in the cellular initiation of coagulation
3. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque
4. Biochemical and molecular aspects of the coagulation cascade
5. Biochemistry and physiology of blood coagulation
6. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes
7. Macrophages, smooth muscle cells, and tissue factor in unstable angina
8. Identification of active tissue factor in human coronary atheroma
9. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques
10. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques
11. Tissue factor in health and disease
12. The tissue factor region that interacts with substrates factor IX and factor X
13. Cofactor residues lysine 165 and 166 are critical for protein substrate recognition by the tissue factor-factor VIIa protease complex
14. Tissue factor residues 157-167 are required for efficient proteolytic activation of factor X and factor VII
15. Lysine residues 165 and 166 are essential for the cofactor function of tissue factor
16. Substrate recognition by tissue factor-factor VIIa. Evidence for interaction of residues Lys165 and Lys166 of tissue factor with the 4-carboxyglutamate-rich domain of factor X
17. Influence of mutations in tissue factor on the fine specificity of macromolecular substrate activation
18. A soluble tissue factor mutant is a selective anticoagulant and antithrombotic agent
19. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis
20. Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model
21. Active site-blocked factor Xa prevents thrombus formation in the coronary vasculature in parallel with inhibition of extravascular coagulation in a canine thrombosis model
22. Antithrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis
23. Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model
24. Antithrombotic efficacy of recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration
25. Relative efficacy of active site-blocked factors IXa, Xa in models of rabbit venous and arteriovenous thrombosis
26. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: Comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants
27. Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time
28. Heparinless cardiopulmonary bypass with active-site blocked factor IXa: A preliminary study in the dog
29. Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats
30. A human antibody that binds to the γ-carboxyglutamic acid domain of factor IX is a potent antithrombotic in vivo
31. Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis
32. Experimental carotid thrombosis in the guinea pig
33. Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis
34. Active site-blocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model
35. Guidelines for the use of animals in biomedical research
36. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries
37. Cloning of guinea pig tissue factor cDNA: Comparison of primary structure among six mammalian species
38. Engineered recombinant factor VII Q217 variants with altered inhibitor specificities
39. Binding of human factor VII and VIIa to monocytes
40. The dual role of factor VII in blood coagulation
41. Mechanistic and pharmacological evaluation of NAPc2, a novel small protein inhibitor of the factor VIIa/tissue factor complex
42. Antithrombotic effect of a monoclonal antibody against tissue factor in a rabbit model of platelet-mediated arterial thrombosis
43. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function
44. Inhibition of tissue factor or intrinsic Xase are effective antithrombotic strategies in a new model of venous thrombosis
45. Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway
46. Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis
47. Local application of recombinant active-site inhibited human clotting factor VIIa reduces thrombus weight and improves patency in a rabbit venous thrombosis model
48. An inhibitory anti-factor IX antibody effectively reduces thrombus formation in a rat model of venous thrombosis
49. Use of phage display for the generation of human antibodies that neutralize factor IXa function
50. Platelet receptor occupancy with factor IXa promotes factor X activation
51. Administration of a humanized monoclonal antibody to factor IX in healthy volunteers
52. Inactivated factor VII, a new antithrombotic treatment: Results from healthy volunteers